Design Therapeutics Inc
$ 13.99
1.60%
07 Aug - close price
- Market Cap 875,517,000 USD
- Current Price $ 13.99
- High / Low $ 14.17 / 13.65
- Stock P/E N/A
- Book Value 3.49
- EPS -1.18
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.34 %
- 52 Week High 17.25
- 52 Week Low 4.23
About
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad, California.
Analyst Target Price
$21.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-03 | 2026-04-28 | 2026-03-09 | 2025-11-05 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-19 | 2023-11-13 |
| Reported EPS | -0.32 | -0.29 | -0.27 | -0.3 | -0.34 | -0.31 | -0.24 | -0.23 | -0.21 | -0.2 | -0.21 | -0.28 |
| Estimated EPS | -0.36 | -0.33 | -0.33 | -0.34 | -0.32 | -0.28 | -0.2667 | -0.24 | -0.23 | -0.26 | -0.31 | -0.42 |
| Surprise | 0.04 | 0.04 | 0.06 | 0.04 | -0.02 | -0.03 | 0.0267 | 0.01 | 0.02 | 0.06 | 0.1 | 0.14 |
| Surprise Percentage | 11.1111% | 12.1212% | 18.1818% | 11.7647% | -6.25% | -10.7143% | 10.0112% | 4.1667% | 8.6957% | 23.0769% | 32.2581% | 33.3333% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DSGN
2026-08-07 21:40:58
The article provides an earnings forecast for Design Therapeutics Inc (DSGN), noting its current earnings forecast score is 8.86, ranking 47 out of 387 in its industry. Analysts have set an average price target of $12.50, with a majority recommending a "Buy" for the stock. The company's previous quarter's EPS was -$0.29, beating the market expectation of -$0.32, and the next quarter's EPS is projected to be -$0.36.
2026-08-07 13:40:58
Renaissance Technologies LLC increased its stake in Design Therapeutics, Inc. (NASDAQ:DSGN) by 42.2% in the first quarter, purchasing an additional 121,100 shares, bringing its total holdings to 408,200 shares valued at approximately $4.34 million. Other institutional investors have also adjusted their positions in the company, which currently has 56.64% institutional ownership. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $16.50, and the company recently beat quarterly earnings estimates.
2026-08-04 02:11:08
Design Therapeutics announced updates on its RESTORE-FA clinical program, modifying the trial to focus on a 1 mpk dose with 12-week data expected in Q1 2027. The company also initiated dosing for its DT-818 in a Phase 1 trial for myotonic dystrophy type 1 and reported second quarter 2026 financial results, including a net loss of $20.2 million and a strong cash position of $207.4 million. Delays in DT-168 supply pushed FECD data to 2027, while preclinical work continues for Huntington's disease.
2026-08-03 23:09:46
Design Therapeutics reported a narrowed net loss for the second quarter, although it did not provide specific figures in the provided document. The company's financial performance indicates an improvement in its loss compared to the previous period.
2026-08-03 13:11:19
Design Therapeutics Inc. reported a net loss of $20.2 million for Q2 2026, or $0.32 per share, with total cash and investments at $207.4 million. The company updated its RESTORE-FA trial for Friedreich ataxia, specifying endogenous blood FXN protein percent change as the primary efficacy endpoint and exploring a higher dose. It also initiated a Phase 1 trial for myotonic dystrophy type 1 and expects data for its Fuchs endothelial corneal dystrophy trial in 2027 due to supply delays.
2026-08-03 08:01:00
Design Therapeutics reported its second-quarter 2026 financial results and provided updates on its clinical programs. The company highlighted progress in its RESTORE-FA trial for Friedreich ataxia, initiating patient dosing for DT-818 in myotonic dystrophy type 1, and advancing preclinical work for Huntington's disease. Design Therapeutics ended the quarter with $207.4 million in cash and securities, providing a strong financial runway.
